Ascidian Therapeutics has entered a research partnership and licensing agreement with Roche to discover and develop RNA exon editing therapies to treat neurological diseases. The partnership will leverage Ascidian’s RNA exon editing platform to extend the therapeutic potential of the medicine beyond the capabilities of current gene editing technologies. The gold standard of business intelligence.
Ascidian will grant Roche sole rights to utilise its RNA exon editing technology for undisclosed neurological targets. Ascidian will conduct discovery and some preclinical works together with Roche. Roche will assume responsibility for additional preclinical activities, alongside clinical development, production and commercialisation of the assets.
Ascidian is entitled to receive an upfront payment of $42m from Roche, and could receive up to $1.8bn in milestone payments on meeting research, clinical and commercial goals. Access the most comprehensive Company Profiles on the market, powered by GlobalData.
Save hours of research. Gain competitive edge. Your download email will arrive shortly We are confident about the unique quality of our Company Profiles.
However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form Ascidian will earn royalty payments on global commercial product sales from Roche. Despite this exclusive arrangement for specific targets, Ascidian can pursue other neurological.